No Data
No Data
Q32 Bio Inc. Patent Woes: Navigating the Perilous Waters of Intellectual Property Disputes
Q32 Bio Analyst Ratings
Wells Fargo Initiates Q32 Bio at Overweight With $95 Price Target
Wells Fargo Initiates Q32 Bio(QTTB.US) With Buy Rating, Announces Target Price $95
Wells Fargo analyst Derek Archila initiates coverage on $Q32 Bio(QTTB.US)$ with a buy rating, and sets the target price at $95.According to TipRanks data, the analyst has a success rate of 45.6% and
Q32 Bio to Participate in Upcoming September Investor Conferences
Piper Sandler Maintains Q32 Bio(QTTB.US) With Buy Rating, Maintains Target Price $60
Piper Sandler analyst Christopher Raymond maintains $Q32 Bio(QTTB.US)$ with a buy rating, and maintains the target price at $60.According to TipRanks data, the analyst has a success rate of 53.9%